All articles by GlobalData 

  1. Nanoparticle conjugates raise hopes for platinum-resistant ovarian cancer patients

    Iowa-based biopharmaceutical company NewLink Genetics showcased its investigational nanoparticle drug conjugate (NDC) at the 2019 American Association for Cancer Research…
    Read More…

    2 May
  2. Eli Lilly remains an attractive proposition through 2019

    Big Pharma experienced a tough year in 2018, with political pricing pressures from regulators and patients forcing companies to reduce…
    Read More…

    1 May
  3. A 10-year overview of ovarian cancer trials

    GlobalData analysed the number of clinical trials examining ovarian cancer with start dates between 1 January 2009 and 21 January…
    Read More…

    1 May
  4. Top ten drugs in biosimilar trials globally

    Over the past decade, the number of clinical trials using a biosimilar treatment has been on the rise. GlobalData extracted…
    Read More…

    1 May
  5. Celgene’s blockbuster Revlimid fails in non-Hodgkin’s lymphoma DLBCL subtype

    On 25 April, Celgene announced top-line results from its Phase III ROBUST trial evaluating Revlimid (lenalidomide) in diffuse large B-cell…
    Read More…

    1 May
  6. Lucrative opportunities await anti-ageing drug developers with deep pockets

    The anti-aging market is currently researching whether or not it is possible for the ageing process to be significantly slowed…
    Read More…

    30 Apr
  7. IBM’s decision to halt sales of Watson AI: strategic move or admission of failure?

    IBM’s disclosure to STAT News on 18 April that it is halting sales of Watson artificial intelligence for drug discovery…
    Read More…

    29 Apr
  8. Neurology market to see an increased focus on rare diseases

    The neurology pipeline has a substantial amount of promising assets. According to GlobalData’s Drug Sales and Consensus Forecast database, half of…
    Read More…

    29 Apr
  9. Success for Mustang Bio’s X-SCID gene therapy could depend on shrewd pricing strategy

    On 18 April, the Phase I/II trial results for Mustang Bio’s gene therapy MB-107 were published in the New England…
    Read More…

    29 Apr
  10. Rise in private equity deals for chemical APIs bucks investment trend

    Investors continue to see the manufacture of chemical APIs as lucrative, despite the growing revenues and interest generated by biologics,…
    Read More…

    26 Apr
Close
Close
Close

Go Top